Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP-1 agonists Clear all

Conditions: Smoking Cessation, Weight, Body
Interventions: Liraglutide, Placebo, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: Rebecca Ashare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
Interventions: RDX-002, Placebo; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 550,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more

Conditions: Overweight or Obesity
Interventions: None - Observational study; Other
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2060
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Severe Obesity, Obesity, BMI Greater Than 30
Interventions: Tirzepatide, Standard of Care post-gastric bypass; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity
Interventions: Medically tailored meals, Noom®, Usual care; Other · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
Interventions: Ultrasound of gastric contents; Diagnostic Test
Lead sponsor: Wael Saasouh, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
Interventions: Semaglutide Injectable Product, Lifestyle Counseling; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: glp1 Agonist, Gene Expression, Skin Laxity
Interventions: ellacor; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dublin, California

Conditions: Wrinkle
Interventions: Skinvive; Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
Interventions: GLP-1, Placebo; Drug
Lead sponsor: AgelessRx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
Interventions: Semaglutide (Rybelsus®), Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type 2
Interventions: Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more

Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Interventions: GLP-1 receptor agonist; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Polycystic Ovary Syndrome, Obesity
Interventions: Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Weight Maintenance
Interventions: Digital Behavioral Application; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Kidney Metabolic Syndrome
Interventions: Intervention, Active Comparator; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 23,280,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Interventions: GLP-1 Receptor Agonists; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gastric Retention
Interventions: Gastric Ultrasound; Diagnostic Test
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic); Drug · Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions: Gastric Fundal Mucosal Ablation (GFMA); Device
Lead sponsor: Dr. Christopher McGowan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions: Gastric Ultrasound Exam; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more

Conditions: Autosomal Dominant Polycystic Kidney, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions: Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Columbus, Ohio • Upper Arlington, Ohio

Search by objective public record fields.

Daily Liraglutide for Nicotine Dependence

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Healthy Living BEYOND Weight Study

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Impact GLP-1 Agonists Following Bariatric

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound

Comparison of Body Composition Changes With Weight Loss Interventions

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Food and Fitness With Medicine (FFWM)